Blank Bio Announces Seed Financing and Strategic Collaboration with PacBio to Advance RNA Foundation Models for Precision Oncology

Key Terms

bulk rna-seq medical

Bulk RNA-seq is a laboratory method that reads all the active gene messages (RNA) from a mixed collection of cells at once, like listening to the combined sound of an orchestra rather than isolating individual instruments. For investors, it matters because the results reveal which genes are turned on or off across a tissue or sample, helping companies identify drug targets, biomarkers, or diagnostic signals at lower cost and higher throughput than single‑cell approaches.

tumor transcriptomes medical

Tumor transcriptomes are the complete collection of RNA messages produced by cancer cells, like a live playlist showing which genes are active at a given moment. They reveal what a tumor is doing now—growth signals, defense mechanisms, or interactions with the immune system—which helps investors judge the potential of diagnostic tests, targeted therapies and trial patient selection that drive commercial value.

long-read technical

A long-read is a single, in-depth news or feature article that explores a business, sector, transaction, or market trend much more deeply than a typical short news item. For investors it provides background, context, and analysis—like a long conversation with an expert—helping reveal underlying drivers, risks and opportunities that short headlines or brief summaries can miss, so readers can make more informed decisions.

hifi long-read technical

High-fidelity long-read sequencing (often called HiFi long-reads) is a DNA sequencing approach that delivers very accurate, unusually long stretches of genetic code in a single pass, combining the clarity of short-read methods with the scope of long-read technologies. For investors, HiFi long-reads matter because they improve the reliability of genetic discoveries, diagnostics and drug target identification—reducing scientific uncertainty much like a high-resolution map reduces navigation errors.

rna-seq medical

RNA sequencing (RNA‑seq) is a laboratory method that reads which genes are active in a tissue or cell by measuring the RNA messages cells produce, like checking which work orders are currently running on a factory floor. Investors care because RNA‑seq can show whether a drug or diagnostic changes disease clues or identifies useful disease indicators, informing clinical decisions, regulatory support and the likely commercial value of a development program.

biomarkers medical

Biomarkers are measurable indicators found in the body, such as substances in blood or tissues, that reveal information about health or disease. For investors, they can signal how well a medical treatment is working or whether a disease is developing, helping to assess the potential success or risks of healthcare companies or innovations. Think of biomarkers as biological signals that provide clues about a person’s health status.

clinical trial design medical

Clinical trial design is the plan for how a medical study is run—who can join, how treatments are given or compared, what is measured and when. Investors care because the design shapes how reliable and fast the results will be; like a building blueprint, a strong design reduces the chance of surprises, clarifies whether a treatment really works or is safe, and therefore affects approval odds, timelines and company value.

isoform medical

Different versions of the same underlying protein that arise from a single gene or closely related genes, like different models built from the same car design with small changes. For investors this matters because which isoform a drug or diagnostic targets can change how well a therapy works, affect safety, alter clinical trial results, and influence patent protection and regulatory approval, all of which can impact a company's future revenues and risk profile.

Collaboration with PacBio will generate long-read bulk RNA-seq data to advance patient-level prediction from tumor transcriptomes

SAN FRANCISCO--(BUSINESS WIRE)-- Blank Bio, an applied AI research lab training foundation models for RNA, today announced the closing of a $7.2 million seed financing and a strategic collaboration with Pacific Biosciences (Nasdaq: PACB), a leading developer of high-quality, highly accurate sequencing solutions. Blank Bio is building RNA foundation models that learn directly from the molecular complexity of tumor transcriptomes to improve patient-level prediction across oncology. Proceeds from the financing will support continued model development, expanded collaborations with pharmaceutical and diagnostic companies, and new long-read RNA-seq datasets to support applications in biomarkers, clinical trial design, and diagnostics.

“Bulk RNA-seq is one of the most clinically accessible and information-rich assays in oncology, but much of its signal is still reduced to simplified gene-level summaries,” said Jonathan Hsu, CEO and Co-Founder of Blank Bio. “Blank Bio was founded to apply foundation models to the full molecular detail contained in each patient’s tumor transcriptome and turn that information into more precise, clinically useful predictions. This financing will support continued model development and partnership expansion, while our collaboration with PacBio will generate the high-resolution long-read RNA data needed to further train and evaluate these models in patient tumor samples.”

Advancing RNA foundation models with high-resolution long-read data

For its strategic collaboration with PacBio, Blank Bio will generate PacBio HiFi long-read, bulk RNA sequencing data from up to 100 fresh frozen patient tumor samples spanning multiple cancer indications. Sequencing will be done at Seattle Children’s Research Institute, where the Kinnex RNA libraries are automated on the SPTLabtech firefly®+ platform. Blank Bio will use the data to further train and evaluate its models, focusing on oncology applications where incorporating RNA-level signals may improve patient stratification, biomarker discovery, and clinical interpretation.

“PacBio HiFi long-read sequencing was built to resolve biology that other technologies miss, and nowhere is that more consequential than in the complex transcriptomes of patient tumors,” said David Miller, Global Vice President of Marketing at PacBio. “Blank Bio’s foundation models demonstrate how high-resolution RNA data and machine learning can advance the next generation of precision oncology applications, from biomarkers and diagnostics to clinical trial design.”

Expanding the analytical foundation for clinical RNA-seq

Bulk RNA-seq is increasingly used across oncology research, drug development, and clinical care because it captures the molecular state of tumor samples at a scale and cost that support clinical deployment. However, standard analytical workflows often compress RNA-seq data into per-gene count summaries, limiting their ability to capture isoform architecture, mutational complexity, and other features of patient-specific tumor biology. Blank Bio is using the seed financing to build the models, datasets, and partnerships that turn this signal into precision oncology products.

Seed financing to support model development, datasets, and partnerships

The oversubscribed round included Define Ventures, Leonis Capital, Nova Threshold, Ripple Ventures, SignalFire, Y Combinator, and others. Proceeds will support continued model development, expanded pharma and diagnostic collaborations, and new data generation efforts.

“Blank Bio is building at the intersection of two major shifts in biology: the expanding clinical use of RNA-seq and the emergence of foundation models capable of learning complex biological patterns at scale,” said Sahir Raoof, TechBio advisor to SignalFire. “The company brings together deep scientific and technical expertise in RNA biology, machine learning, and oncology, with a platform that has the potential to turn transcriptomic data into a more powerful layer of patient-level insight for drug development and diagnostics.”

The Blank Bio team includes AI scientists and engineers from companies including Recursion, Deep Genomics, DeepMind, and Amazon, and institutions including Memorial Sloan Kettering Cancer Centre, Stanford, and the Vector Institute. The team has published work in Nature Methods, Nature Genetics, Nature Biotechnology, ICML, and NeurIPS, including Orthrus, its prior academic work on RNA foundation models, recently published in Nature Methods.

About Blank Bio’s RNA Foundation Models

Blank Bio is deploying its RNA foundation models across three primary areas. In predictive biomarkers, the company supports pharma teams in characterizing trial populations, identifying likely responders, and selecting patients to improve trial success. In prognostic biomarkers and patient trajectory modeling, the models use tumor molecular profiles to predict disease progression for risk stratification and clinical trial design. In clinical diagnostics, Blank Bio is working with leading diagnostic companies to augment existing RNA-seq tests and improve sensitivity and specificity.

About Blank Bio

Blank Bio is an applied AI research lab training foundation models to capture patient heterogeneity through the transcriptome. The company's models extract patient-level variation from clinical bulk RNA-seq that per-gene count pipelines discard. Blank Bio partners with pharmaceutical and diagnostic companies to identify the right patient populations for therapeutic assets, predict individual disease trajectories, and support RNA-seq-based clinical diagnostics. For more information, please visit www.blank.bio and connect on LinkedIn.

About PacBio

PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies, which include our HiFi long-read sequencing, address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow @PacBio.

PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260513274683/en/

Company: hello@blank.bio
Media: Jessica Yingling, Ph.D., Little Dog Communications Inc., jessica@litldog.com

Source: Blank Bio